Table 1. Clinical, pathological, molecular features in AC tumors.

Patient ID	Histology	Sex	Age (years)	Functional status	Tumor volume (g)	Tumor stage	IHC status of β-catenin (nuclear/cytoplasm)	β-catenin mutation	Wif-1 methylation
1	ACC	M	70	NF	357	IV	Neg.	No	Yes
2	ACC	F	33	NF	110	III	Pos. (nuclear)	No	Yes
3	ACC	M	68	NF	4	I	Pos. (cytoplasm)	No	Yes
4	ACA	F	58	NF	2	-	Pos. (cytoplasm)	No	No
5	ACA	F	63	NF	7	-	Pos. (cytoplasm)	No	No
6	ACA	F	47	NF	6	-	Pos. (cytoplasm)	No	No
7	ACA	M	73	NF	25	-	Neg.	No	Yes
8	ACA	F	50	NF	8	-	Neg.	No	Yes
9	ACA	F	56	NF	10	-	Pos. (cytoplasm)	No	Yes
10	ACA	M	48	NF	50	-	Pos. (nuclear)	L46P	Yes
11	ACA	M	71	NF	17	-	Neg.	No	Yes
12	ACA	M	70	NF	12	-	Pos. (cytoplasm)	No	No
13	ACA	M	67	NF	9	-	Pos. (nuclear)	P44A S45P	No
14	ACA	M	60	NF	1	-	Pos. (cytoplasm)	No	Yes
15	ACA	M	62	NF	30	-	Pos. (cytoplasm)	No	Yes
16	ACA	M	50	NF	4	-	Pos. (cytoplasm)	No	No
17	ACA	F	46	NF	6	-	Pos. (cytoplasm)	No	Yes
18	ACA	F	70	NF	23	-	Neg.	No	Yes
19	ACA	F	80	NF	20	-	Pos. (nuclear)	No	Yes
20	ACA	F	45	ALD	10	-	Neg.	No	Yes
21	ACA	M	52	ALD	28	-	Neg.	No	No
22	ACA	F	57	ALD	7	-	Pos. (cytoplasm)	No	No
23	ACA	F	55	ALD	13	-	Pos. (cytoplasm)	No	No
24	ACA	M	53	ALD	9	-	Neg.	No	No
25	ACA	F	64	ALD	14	-	Pos. (nuclear)	No	Yes
26	ACA	F	63	ALD	9	-	Neg.	No	Yes
27	ACA	F	69	ALD	6	-	Neg.	No	No
28	ACA	M	32	ALD	23	-	Neg.	No	No
29	ACA	F	42	ALD	6	-	Neg.	No	Yes
31	ACA	M	52	ALD	7	-	Pos. (cytoplasm)	No	Yes
31	ACA	F	58	ALD	5	-	Neg.	No	No
32	ACA	F	65	ALD	5	-	Neg.	No	No
33	ACA	M	62	ALD	19	-	Neg.	No	No
34	ACA	F	39	ALD	5	-	Neg.	No	Yes
35	ACA	F	46	ALD	11	-	Neg.	No	No
36	ACA	M	59	COR	27	-	Neg.	No	No
37	ACA	F	56	COR	42	-	Neg.	No	Yes
38	ACA	F	51	COR	7	-	Neg.	No	Yes
39	ACA	F	62	COR	8	-	Pos. (cytoplasm)	No	Yes
40	ACA	F	21	COR	15	-	Neg.	No	No
41	ACA	M	76	COR	6	-	Neg.	No	Yes
42	ACA	F	58	COR	5	-	Pos. (nuclear)	No	Yes

ACC, Adrenocortical carcinoma; ACA, adrenocortical adenoma; M, male; F, female; NF, nonfunctioning; ALD, aldosterone; COR, cortisol; IHC, immunohistochemistry.